跳至主要内容
临床试验/NCT05196191
NCT05196191终止不适用

Randomized Control Trial of Vivex Tissue for Accelerated Wound Healing Following Penile Prosthesis Placement With Follow-up

VIVEX Biologics, Inc.2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2022年1月3日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
32
试验地点
2
主要终点
Penile implant activation

研究概览

简要总结

This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on men undergoing penile implant surgery for the first time. The patients are randomized in a 2:1 ratio of active to sham treatment groups.

详细描述

Erectile Dysfunction (ED) is a condition with an inability to develop or maintain an erection of the penis upon sexual stimulation. It occurs in association with aging, chronic illnesses and various modifiable risk factors. Amongst the modifiable risk factors, ED shares the most common risk factors with Coronary Artery Disease (CAD) which are smoking, hypertension and hyperlipidemia. Even though it is not a part of normal aging, it is seen in 52% of men in the age group 40 to 70 years, with a higher rate in the men more than 70 years.

VIAGENEX Max is a semi-transparent, collagenous membrane intended for soft tissue barrier or wound covering, derived from umbilical cord membrane. A total of 50 subjects with ED meeting the eligibility criteria will be randomized. The treatment graft will be placed into the wound at time of surgery. The treatment group will receive the VIAGENEX graft and the sham group will receive the standard of care for this surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Subjects will not be told which treatment group they receive until the end of study participation.

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • The patient must be willing and able to provide informed consent
  • The patient is a male between >/= 30 and =/< 70 years of age
  • The patient has ED based of International Index of Erectile Dysfunction (IIEF) scores
  • The patient has been in a stable relationship for over 3 months prior to enrollment
  • A minimum of 2 sexual attempts per month for at least one month prior to enrollment - as documented by IIEF
  • The patient is suffering from erectile dysfunction and undergoing penile implant surgery for the first time
  • IIEF-EF score between 16 and 25
  • Testosterone level 300-1000 ng/dL within 1 month prior to enrollment
  • A1C level </= 7% within 1 month prior to enrollment

排除标准

  • The patient is currently or has participated in another study within the past three months that may interfere with the results or conclusions of this study
  • The patient is under judicial protection (prison or custody)
  • The patient is an adult under guardianship
  • The patient refuses to sign the consent
  • History of radical prostatectomy or extensive pelvic surgery
  • Evidence of venous leak
  • Past radiation therapy of the pelvic region within 12 months prior to enrollment
  • Recovering from any cancer within 12 months prior to enrollment
  • Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function at the discretion of the investigator
  • Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications at the discretion of the investigator
  • Anatomical malformation of the penis, including Peyronie's disease
  • Testosterone level <300 or >1000 ng/dL within 1 month prior to enrollment
  • A1C level > 7% within 1 month prior to enrollment or history of insulin dependent diabetes
  • The patient is taking blood thinners and has an international normalized ratio >3
  • Received shockwave treatment at least 6 months before enrollment

结局指标

主要结局

Penile implant activation

时间窗: up to 3 months

Time to use implant for sexual activity

次要结局

  • Pain after undergoing penile prosthesis surgery(surgery to 12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验